Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
NCT06502977
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
32
Enrollment
INDUSTRY
Sponsor class
Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
DRUG:
Tarlatamab
Sponsor
Amgen